Comparative double-blind trial of dl-alpha-tocopheryl nicotinate on vibration disease.
Sixty inpatients with vibration disease were examined on the effect of dl-alpha-tocopheryl nicotinate by comparative double-blind study. The observed period was 6 weeks and the dose was 6 capsules a day (600 mg as dl-alpha-tocopheryl nicotinate, Juvela Nicotinate, referred to as EN). The physical exercise therapy was applied to all patients throughout the test period. EN group became better with a significant difference from P (placebo) group in the subjective symptoms, the clinical examinations and the collective improving rate (p less than 0.01, 0.05, 0.01), respectively. The improvement of the subjective symptoms of both groups was higher 6 weeks than 3 weeks after administration. Most items in EN group became better significantly (p less than 0.05) as compared with those in P group. The examinations of the peripheral functions in EN group showed a significant improvement 6 weeks after administration in comparison with those in P group. Blood chemistry, blood cell counts and serum electrolytes changed within normal range. Thus, this preparation would be a curative agent for patients with vibration disease.
D002986:Clinical Trials as Topic; D005081:Exercise Therapy; D006801:Humans; D008297:Male; D009539:Nicotinic Acids / Q000627:therapeutic use*; D011928:Raynaud Disease / Q000188:drug therapy* / Q000628:therapy; D012881:Skin Temperature; D014732:Vibration / Q000009:adverse effects*; D014810:Vitamin E / Q000627:therapeutic use* / Q000031:analogs & derivatives
D009539:Nicotinic Acids; D014810:Vitamin E; C012581:alpha-tocopheryl nicotinate